Source-grounded facts extracted from Mirum Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Mirum Pharmaceuticals, Inc. shareholders approved Advisory vote on executive compensation at the 2026-06-15 meeting.
“The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement for the Annual Meeting.”
Mirum Pharmaceuticals, Inc. shareholders approved Ratification of the selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-06-15 meeting.
“The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Mirum Pharmaceuticals, Inc. shareholders approved Election of three Class I directors at the 2026-06-15 meeting.
“The Company’s stockholders elected the three persons listed below as Class I directors, each to serve until the Company’s 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal.”
Mirum Pharmaceuticals, Inc. entered into Indenture with U.S. Bank Trust Company, National Association valued at $690.0 million (effective 2026-05-15).
“On May 15, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) issued $690.0 million aggregate principal amount of its 0.00% Convertible Senior Notes due 2032 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $90.0 million aggregate principal amount of Notes. The Notes were issued pursuant to, and are governed by, an indenture (the “Indenture”), dated as of May 15, 2026, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”).”
Mirum Pharmaceuticals, Inc. incurred convertible notes of $690.0 million aggregate principal amount with U.S. Bank Trust Company, National Association at 0.00% maturing June 1, 2032.
“On May 15, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) issued $690.0 million aggregate principal amount of its 0.00% Convertible Senior Notes due 2032”
Mirum Pharmaceuticals, Inc. reported the quarter ended March 31, 2026 results: revenue $159.9 million. Guidance raised.
“in such filing. --- EX-99.1 (EX-99.1) --- Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update – Q1 2026 net product sales of $159.9 million – 2026 net product sales guidance increased to $660 to $680 million – Volixibat VISTAS Phase 2b study met primary endpoint – Brelovitug Phase 2b portion of AZURE-1 study met”
Mirum Pharmaceuticals, Inc. completed an acquisition involving Bluejay Therapeutics, Inc. for up to an aggregate amount of (i) $280.8 million in cash and (ii) 4,673,597 shares of Company common stock (closed 2026-01-23).
“of the Mergers, the Company acquired Target’s net cash of approximately $56.6 million and paid or will pay to the holders of Target’s securities up to an aggregate amount of (i) $280.8 million in cash and (ii) 4,673,597 shares of Company common stock, subject to the Company’s receipt of deliverables that are a condition to payment and deduction to satisfy applicable”
Mirum Pharmaceuticals, Inc. entered into Subscription Agreement with entities associated with TCG Crossover Management, LLC valued at approximately $68,480,000 (effective 2025-12-18).
“On December 18, 2025, Mirum Pharmaceuticals, Inc. (the “Company”) entered into a subscription agreement (the “Subscription Agreement”) with entities associated with TCG Crossover Management, LLC (“TCGX”), an institutional investor (the “PIPE Investors”), pursuant to which the PIPE Investors have agreed, subject to the terms and conditions of the Subscription Agreement, to purchase immediately following the Closing (as defined below), 1,000,000 shares (the “PIPE Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for an aggregate gross purchase price of approximately $68,480,000 (the “Private Placement”).”
Mirum Pharmaceuticals, Inc. issued 1,000,000 shares of common stock to entities associated with TCG Crossover Management, LLC for aggregate gross purchase price of approximately $68,480,000.
“On December 18, 2025, Mirum Pharmaceuticals, Inc. (the “Company”) entered into a subscription agreement (the “Subscription Agreement”) with entities associated with TCG Crossover Management, LLC (“TCGX”), an institutional investor (the “PIPE Investors”), pursuant to which the PIPE Investors have agreed, subject to the terms and conditions of the Subscription Agreement, to purchase immediately following the Closing (as defined below), 1,000,000 shares (the “PIPE Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for an aggregate gross purchase price of approximately $68,480,000 (the “Private Placement”).”
Mirum Pharmaceuticals, Inc. entered into Agreement and Plan of Merger and Reorganization with Bluejay Therapeutics, Inc. valued at an upfront amount of $250 million in cash and up to 5,196,009 shares of Company common stock (effective 2025-12-06).
“On December 6, 2025, Mirum Pharmaceuticals, Inc. (the “Company”) entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Bjork Merger Sub I, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company (“Merger Sub I”), Bjork Merger Sub II, LLC, a Delaware limited liability company and a direct wholly owned subsidiary of the Company (“Merger Sub II” and, together with Merger Sub I, the “Merger Subs”), Bluejay Therapeutics, Inc., a Delaware corporation (“Target”), and Fortis Advisors LLC, a Delaware limited liability company, solely in its capacity as the representative, agent and attorney in fact of the Target security holders”
Mirum Pharmaceuticals, Inc. reported the quarter ended March 31, 2024 results: revenue $69.2 million. Guidance reaffirmed.
“such filing. --- EX-99.1 (EX-99.1) --- Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update • First quarter 2024 total revenue of $69.2 million, on track to achieve full-year guidance of $310 to $320 million • FDA approval of LIVMARLI for cholestatic pruritus in PFIC patients achieved in March • Volixibat VISTAS and”
Mirum Pharmaceuticals, Inc. updated its the quarter and year ended December 31, 2023 guidance (raised).
“On February 28, 2024, Mirum Pharmaceuticals, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the quarter and year ended December 31, 2023.”
Christopher Peetz changed role as Chief Executive Officer at Mirum Pharmaceuticals, Inc..
“On January 11, 2024, the Board of Directors of Mirum Pharmaceuticals, Inc. (the “Company”) promoted Peter Radovich, previously the Company’s Chief Operating Officer, to the additional position of President, with Christopher Peetz, who previously served as the Company’s President and Chief Executive Officer, continuing to serve as the Company’s Chief Executive Officer, each effective as of January 16, 2024.”
Peter Radovich changed role as President at Mirum Pharmaceuticals, Inc..
“On January 11, 2024, the Board of Directors of Mirum Pharmaceuticals, Inc. (the “Company”) promoted Peter Radovich, previously the Company’s Chief Operating Officer, to the additional position of President, with Christopher Peetz, who previously served as the Company’s President and Chief Executive Officer, continuing to serve as the Company’s Chief Executive Officer, each effective as of January 16, 2024.”
Mirum Pharmaceuticals, Inc. reported the fiscal year ended December 31, 2023 results: revenue $186-188 million.
“Report on Form 8-K. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates - $186-188 million in total revenue and $178-180 million net product sales expected for 2023, preliminary and unaudited - LIVMARLI net products sales of $141-143 million expected”
Mirum Pharmaceuticals, Inc. reported third quarter 2023 results: revenue $47.7 million.
“EXHIBIT 99.1 Exhibit 99.1 Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update - Third quarter 2023 total revenue of $47.7 million - Completed acquisition of CHENODAL® and CHOLBAM® - Announced positive Phase 3 RESTORE study results evaluating CHENODAL (chenodiol) in patients with CTX; NDA filing expected in”
Eric Bjerkholt was appointed as Chief Financial Officer at Mirum Pharmaceuticals, Inc..
“On September 11, 2023, Mirum Pharmaceuticals, Inc., (the “Company”) announced that the Board of Directors of the Company (the “Board”) appointed Eric Bjerkholt as the Chief Financial Officer of the Company, including as the “principal financial officer” of the Company within the meaning of Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, effective September 11, 2023 (the “Appointment Date”).”
Mirum Pharmaceuticals, Inc. completed an acquisition involving Travere Therapeutics, Inc. for an upfront purchase price of $210,000,000 in cash (closed 2023-08-31).
“(the “Purchase Agreement”), dated July 16, 2023, by and between the Company and Travere. Under the terms of the Purchase Agreement, the Company paid an upfront purchase price of $210,000,000 in cash to Travere at the Asset Purchase Closing using cash and cash equivalents from the Company’s balance sheet. The Company may pay Travere up to $235,000,000 after the Asset”
Mirum Pharmaceuticals, Inc. reported the quarter ended June 30, 2023 results: revenue $37.5 million.
“Total revenue for the quarter ended June 30, 2023 was $37.5 million, including $5.0 million of license revenue, compared to $17.5 million in total revenue for the quarter ended June 30, 2022.”
Mirum Pharmaceuticals, Inc. entered into Subscription Agreements with certain parties (the "PIPE Investors") valued at an aggregate purchase price of approximately $210,000,000 at a price per share equal to $26.25 (effective 2023-07-16).
“Concurrently with the execution and delivery of the Purchase Agreement, certain parties (the “PIPE Investors”) have entered into subscription agreements (the “Subscription Agreements”) with the Company, pursuant to which they have agreed, subject to the terms and conditions of the Subscription Agreements, to purchase immediately prior to, but subject to, the consummation of the Asset Purchase, shares of the Company’s common stock, par value $0.0001 per share (the “PIPE Shares”) for an aggregate purchase price of approximately $210,000,000 at a price per share equal to $26.25, the closing price of the Company’s common stock on July 14, 2023 (the “Private Placement”).”
Mirum Pharmaceuticals, Inc. entered into Purchase Agreement with Travere Therapeutics, Inc. valued at up to $445,000,000 in cash, with $210,000,000 due at Closing and up to $235,000,000 after the Closin (effective 2023-07-16).
“On July 16, 2023, Mirum Pharmaceuticals, Inc. (the “Company”) executed an Asset Purchase Agreement (the “Purchase Agreement”) with Travere Therapeutics, Inc., a Delaware corporation (“Travere”).”
Mirum Pharmaceuticals, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-06-12 meeting.
“Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 34,194,852 3,376 28,240”
Mirum Pharmaceuticals, Inc. shareholders approved Election of Directors at the 2023-06-12 meeting.
“Proposal 1. Election of Directors The Company’s stockholders elected the three persons listed below as Class I directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Lon Cardon 30,587,478 410,063 3,228,927 William Fairey 30,362,034 635,507 3,228,927 Timothy Walbert 27,482,518 3,515,023 3,228,927”
Mirum Pharmaceuticals, Inc. reported first quarter 2023 results: revenue $31.6 million total revenue, including net product sales for LIVMARLI® (maralixibat) oral solution of $29.1 million.
“Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update - $31.6 million total revenue, including net product sales for LIVMARLI ® (maralixibat) oral solution of $29.1 million, for first quarter 2023”
Mirum Pharmaceuticals, Inc. incurred convertible notes of $316.25 million at 4.00% per annum maturing May 1, 2029.
“On April 17, 2023, Mirum Pharmaceuticals, Inc. (the “Company”) issued $316.25 million principal amount of its 4.00% Convertible Senior Notes due 2029”
Mirum Pharmaceuticals, Inc. entered into Purchase Agreement with the initial purchasers of the Notes valued at $41.25 million principal amount of Notes.
“Pursuant to the purchase agreement among the Company and the initial purchasers of the Notes (the “Purchase Agreement”), the Company granted the initial purchasers an option to purchase, for settlement within a period of 13 days from, and including, the date the Notes are first issued, up to an additional $41.25 million principal amount of Notes.”
Mirum Pharmaceuticals, Inc. entered into Indenture with U.S. Bank Trust Company, National Association, as trustee valued at $316.25 million principal amount of its 4.00% Convertible Senior Notes due 2029 (effective 2023-04-17).
“On April 17, 2023, Mirum Pharmaceuticals, Inc. (the “Company”) issued $316.25 million principal amount of its 4.00% Convertible Senior Notes due 2029 (the “Notes”). The Notes were issued pursuant to, and are governed by, an indenture (the “Indenture”), dated as of April 17, 2023, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”).”
Mirum Pharmaceuticals, Inc. reported first quarter of 2023 results: revenue approximately $31.5 million of total revenue, consisting of approximately $29.0 million of product sales, net, and appro.
“The company’s preliminary unaudited financial results for the first quarter of 2023 include: • Approximately $31.5 million of total revenue, consisting of approximately $29.0 million of product sales, net, and approximately $2.5 million of license revenue, for the three months ended March 31, 2023;”
Niall O'Donnell resigned as Director at Mirum Pharmaceuticals, Inc..
“On April 5, 2023, Niall O’Donnell, Ph.D., notified the board of directors (the “Board”) of Mirum Pharmaceuticals, Inc. (the “Company”) of his resignation as a director of the Company and as a member of the Nominating and Corporate Governance Committee of the Board, in each case, effective as of the date of the Company’s 2023 Annual Meeting of Stockholders.”
Timothy Walbert was appointed as Director at Mirum Pharmaceuticals, Inc..
“On April 5, 2023, the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Timothy Walbert to the Board, effective immediately.”
Mirum Pharmaceuticals, Inc. reported Fourth quarter 2022 results: revenue $27 million estimated product sales.
“Fourth quarter 2022 estimated product sales of $27 million includes an estimated $5 million of international sales through partner market supply orders, including inventory;”
Mirum Pharmaceuticals, Inc. reported 2022 results: revenue $76 million total revenue.
“$76 million in total revenue and $74 million net product sales anticipated for LIVMARLI for 2022, preliminary and unaudited”
Ian Clements departed as Chief Financial Officer at Mirum Pharmaceuticals, Inc..
“Dr. Clements will resign as Chief Financial Officer of the Company.”
Lon Cardon was appointed as Director at Mirum Pharmaceuticals, Inc..
“On December 19, 2022, the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Lon Cardon, Ph.D., FMedSci, to the Board, effective immediately.”
Carol L. Brosgart resigned as Director at Mirum Pharmaceuticals, Inc..
“On December 16, 2022, Carol L. Brosgart, M.D., notified the board of directors (the “Board”) of Mirum Pharmaceuticals, Inc. (the “Company”) of her resignation as a director of the Company and as a member of the Nominating and Corporate Governance Committee of the Board, effective December 19, 2022.”
Mirum Pharmaceuticals, Inc. reported the quarter ended September 30, 2022 results: revenue $18.8 million, net income net loss of $35.7 million, EPS $1.02 basic and diluted net loss per share.
“99.1 Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update - Net product sales for LIVMARLI ® (maralixibat) oral solution totaled $18.8 million in the third quarter of 2022 and $47.2 million year-to-date - Mirum raises 2022 full year net product sales guidance estimate for LIVMARLI to $70 million - Conference call to”
Edward T. Mathers resigned as director at Mirum Pharmaceuticals, Inc..
“On September 1, 2022, Edward T. Mathers notified the board of directors (the “Board”) of Mirum Pharmaceuticals, Inc. (the “Company”) of his resignation as a director of the Company and as a member of the Compensation Committee of the Board, effective September 1, 2022.”
Saira Ramasastry was appointed as Director at Mirum Pharmaceuticals, Inc..
“On June 2, 2022, the Board of Directors (the "Board") of Mirum Pharmaceuticals, Inc. (the "Company"), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Saira Ramasastry to the Board, effective immediately.”
William Fairey was appointed as Director at Mirum Pharmaceuticals, Inc..
“On August 19, 2021, the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed William Fairey to the Board, effective immediately.”
Tiba Aynechi resigned as Director at Mirum Pharmaceuticals, Inc..
“On August 16, 2021, Tiba Aynechi, Ph.D. notified the board of directors (the “Board”) of Mirum Pharmaceuticals, Inc. (the “Company”) of her resignation as a director of the Company, effective August 19, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.